Skip Ribbon Commands
Skip to main content
Menu

Current Clinical Trials

For enquiries, please email clinical.trials@nccs.com.sg

Phase 1


No Site​ ​Stage of cancer Title of study ​Principal investigator ​Details of trial ​Status
​1​All Solid Tumour​IV

​D3-002
A Phase 1A/B study to evaluate the safety and tolerability of ET-1922159 in advanced solid tumours

​Dr Matthew Ng NCT02521844 ​Open
2Epithelial sarcoma, NPC, Gastric, Prostate Ovarian & DLBCLIV​CMAK683X2101
A Phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies
​Dr Daniel Tan NCT02900651​Open
​3Brain​IV​CBLZ945X2101
A Phase I/II, open-label, multi-center of the safety and efficacy of BZL945 as single agent and in combination with PDR001 in adults patients with advanced solid tumors malignancies.
​Dr Darren Lim NCT02829723​Closing
​4​NSCLC, Head and Neck, GIST, CRC, Esophageal IV​CTNO155X2101
An Open-label, multi-center, Phase I, dose finding study of oral TNO155 in adult patients with advanced solid tumors
​Dr Daniel TanNCT03114319​Open
​5​​CRC and PDAC​​Advanced​CTMT212XSG01T
Phase Ib study evaluating safety and tolerability of combination trametinib and ruxolitinib in patients with advanced RAS mutant colorectal cancer and pancreatic adenocarcinoma
​Dr David TaiNCT04303403​Open
​6​​Lung​​LOCALLY ADVANCED/ METASTATIC - First LineCPDR001C2101
Phase 1b, multicenter, open label, 3 arm, dose de-escalation study of PDR001 in combination with platinum-doublet chemotherapy in 1st line, PD-L1 unselected, NSCLC patients
​Dr Daniel TanNCT03064854​Open
​7​​All Solid Tumour​documented RET infusionLOXO-RET-17001
A Phase 1 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity
​Dr Daniel TanNCT03157128​Open
8​​All Solid Tumour​documented RET infusionBLU-667-1101
A Phase 1 Study of the Highly-selective RET inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumours
​Dr Daniel TanNCT03037385​Open
9NSCLC, Pancreas and all solid tumors ​IVMCLA-128-CL01
A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors
​Dr Justina Lam NCT02912949​Open
10​All Solid Tumour with documented NTRK fusions ​must had prior TRK inhibitorLOXO-EXT-17005
A Phase 1/2 study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects with Previously Treated NTRK fusion cancers
​Dr Daniel Tan NCT03215511Open
11NSCLC, TNBC, PDAC, RCC, Ovarian, CRC, Prostate​IVCNZV930X2101
A Phase I/Ib, open-label, multi-center study of NZV930 as a single agent and in combination with PDR001 and/or NIR178 in patients with advanced malignancies
Dr Koo Si-Lin NCT03549000​Open
12​​All Solid Tumour​with documented ATM lossBAY 1895344 / 18594
An open-label, first-in-human, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose and / or recommended Phase II dose of the ATR inhibitor BAY 1895344 in patients with advanced solid tumors and lymphomas
​Dr Daniel Tan NCT03188965​On hold
13​BreastTNBC, not more than 2 prior lines of chemotherapy. Neoadjuvant or adjuvant chemotherapy will count as one prior line.CADPT01A12101C
A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select immunotherapy combinations in adult patients with triple negative breast cancer
​Dr Tira Tan NCT03742349​Open
14​NSCLC​Advanced recurrentBI 1200.275
A dose finding study of continuous and intermittent high-dose (HDI) Afatinib (EGFR Tyrosine Kinase Inhibitor) on CNS metastases and leptomeningeal disease (LMD) in patients with advanced refractory EGFR mutation positive non-small cell lung cancer
​Dr Daniel Tan NCT03711422Closing
15​NSCLC​​with documented EGFR Exon 20 insertion mutation CLN-081-001
 A Phase 1/2a, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
​Dr Daniel TanNCT04036682​Open
​16​NSCLC​​with documented KRASV941-001
 A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination with Pembrolizumab in Participants with KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma
​Dr Daniel TanNCT03948763​Open
17​Prostate​​Advanced recurrentAmgen 20180101
 A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager AMG 160 in Subjects With Metastatic Castration-resistant Prostate Cancer
​Dr Daniel TanNCT03792841​Open
18​​All Solid Tumour​documented RET infusionLIBRETTO-201
A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation
​Dr Daniel TanNCT03906331Open
19​All Solid Tumour​​​Advanced recurrentTHOR-707-101
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and in a Combination Therapy in Adult Subjects with Advanced or Metastatic Solid Tumors
​Dr Tira TanNCT04009681​On hold
20​Ovarian​RecurrentNCC OV-03 (BMS Protocol No. CA209-7WC)
A Phase I/II Clinical Trial to Evaluate Platinum-based Chemotherapy, Oregovomab and Nivolumab in Patients with Platinum Sensitive Recurrent Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin (ORION-02)
​Dr Jack ChanNCT04620954​Open
21​​​​Melanoma/NSCLC/
esophageal
​IVNP41300
An Open Label, Multicenter, Dose Escalation, Phase 1 Study to Evaluate Safety/ Tolerability, Pharmacokinetics and Preliminary Anti Tumor Activity of RO7247669, A PD1-LAG3 Bispecific Antibody, in Patients with Advanced and/or Metastatic Solid Tumors
​Dr Darren LimNCT04140500​Open
22​All Solid Tumour​​Advanced recurrentTAPISTRY
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational For You (TAPISTRY) Phase II Platform Trial
​Dr Tira TanNCT04589845Open
23​All Solid Tumour​Advanced recurrentAmgen 20180143
A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 404, a Programmed Death-1 (PD-1) Antibody, in Patients With Advanced Solid Tumors
​Dr Daniel Tan​NCT03853109​Open
24​​​All Solid Tumour​Advanced recurrentCJDQ443A12101
A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in advanced solid tumor patients harboring the KRAS G12C mutation
​​Dr Daniel TanNCT04699188
​Open

Current clinical trials by body parts

No Site​ ​Stage of cancer ​Title of study ​Principal investigator Details of trial Status
1​Bladder​Unresectable or Metastatic Urothelial CancerCA209-901
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
​Dr Ravindran Kanesvaran NCT03036098​Open
2​​BladderNeoadjuvant and adjuvant chemotherpay for non-muscle invasive bladder cancerCA017-078
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants  with Muscle-Invasive Bladder Cancer
​Dr Ravindran KanesvaranNCT03661320​Open
3​Breast​premenopausal perimenopausal
HR+
LABC
MBC
​CLEE011A3201C
A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptor-positive/HER2-negative inoperable locally advanced or metastatic breast cancer - RIGHT Choice Study
Dr Yap Yoon Sim NCT03839823  Open
4​Breast ​MetastaticBEXMET
Metastatic Triple-Negative Taxane-Resistant Breast Cancer: Investigating the Role of Bexarotene in Inducing Susceptibility to Chemotherapy by Differentiating Cancer Cells from a Mesenchymal-Like to an Epithelial-Like Phenotype
​Dr Elaine Lim​NCT04664829​Open
5​​Breast

​Neo adj

HER2 Neg 

ER+

tx naive

high risk

stage II/III

CA209-7FL
A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in the Treatment of High-risk, Stage II-III Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Breast Cancer
​Dr Yap Yoon Sim NCT0410906​Open
6​BreastPIK3 CA-Mutant HR+, HER2 - LABC/MBCWO41554
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GDC 0077 Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant In Patients with Locally Advanced or Metastatic Pik3ca-Mutant Hormone Receptor-Positive, Her2 Negative Breast Cancer
Dr Yap Yoon Sim NCT04191499       ​Open
7​Breast ​Adjuvant / Metastatic TCF20-BRE-01
An open-label, single-institution, dose-determining (Part I) and dose-confirmatory (Part II) study to investigate the optimal dose of Tamoxifen in breast cancer patients harboring different TCF20 rs932376 variant alleles
​Dr Elaine Lim​Pending​Open
8​Breast​HER2 Neg                          ER +  , 1st line                             LABC/MBC

EFC15935-AMEERA-5

A randomized, multicenter, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER(+), HER2(-) breast cancer who have not received prior systemic anti-cancer treatment for advanced disease

​Dr Yap Yoon SimNCT04478266​Open
​9​Breast​TNBCWO39391-IMPASSION 030
A Phase III, Multicenter, Randomized, Open-label Study Comparing ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) In Combination With Standard Adjuvant ANTHRACYCLINE/TAXANE-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable TRIPLE-NEGATIVE Breast Cancer
​Dr Rebecca DentNCT03498716​Open
​10​Breast​ER +, HER2-       LABC or MBCWO42312
A Phase II, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Compared With Physician's Choice of Endocrine Monotherapy in Patients with Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
​Dr Yap Yoon SimNCT04576455​Open
​11​Breast​HER2+ AdjWO42633-Astefania:
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Atezolizumab or Placebo in Combination with Trastuzumab Emtansine as Adjuvant Therapy for Patients with HER2-Positive Primary Breast Cancer At Risk of Recurrence Who have Residual Tumor Present Pathologically in the Breast and/or Axillary Lymph Nodes Following Preoperative Therapy
​Dr Yap Yoon SimNCT04873362​Open
​12​Breast​HER2 +DESTINY-Breast05:
A Phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in subjects with high-risk HER2positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes following neoadjuvant therapy
​Dr Tira TanNCT04622319​Open
13​Colorectal​NeoadjuvantOTSP-WoOCRC / MK-3475-886
Window of Opportunity Study with Neoadjuvant Pembrolizumab in MSS & MSI Colorectal Cancer
​Dr Iain Tan NCT03984578​Open
14​Endometrial​HER 2 recurrent advanced or mets endometrial carcinoma

SYD985.003

A phase II study to compare the safety and efficacy of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-expressing recurrent advanced or metastatic endometrial carcinoma who previously progressed on or after first line platinum-based chemotherapy

​Dr Chay Wen YeeNCT04205630​Open
15​Gynae​Endometrial Ca Newly advanced or recurrent CaD9311C00001 (DUO-E)
A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer
​Dr Soh Lay TinNCT04269200​Open
16​Esophageal​Unresectable Locally Advanced, Unresectable Recurrent,  Metastatic, 1st lineYO42138
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of Atezolizumab Plus Tiragolumab In Combination With Paclitaxel And Cisplatin Compared With Paclitaxel And Cisplatin As First-Line Treatment In Patients With Unresectable Locally Advanced, Unresectable Recurrent, Or Metastatic Esophageal Squamous Cell Carcinoma
​Dr Matthew NgNCT04540211Open
17​Gastric
​NeoadjuvantINNOVATION
INtegratioN of trastuzumab, with or without pertuzumab, into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer (EORTC-1203-GITCG)
​​​Dr Matthew Ng NCT02205047​Open
18​​Gastric/ Gastroesophageal JunctionMetastatic or locally advancedCP-MGAH22-06
A Phase 2/3 Trial to Evaluate Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients with Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer
Dr Matthew Ng NCT04082364​On hold
19​Liver​AdjuvantWO41535
A Phase III, Multicenter, Randomized, Open-Label Study Of Atezolizumab (Anti-Pd-L1 Antibody) Plus Bevacizumab Versus Active Surveillance As Adjuvant Therapy In Patients With Hepatocellular Carcinoma At High Risk Of Recurrence After Surgical Resection Or Ablation
​Dr Toh Han ChongNCT04102098​Open
20​Liver​Adv 1st lineEMERALD-1
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma
​Dr David TaiNCT03778957On hold
21​Liver​Advance/ Metastatic  2nd lineCA224-073
A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase Inhibitors
​Dr David TaiNCT04567615​Open
22​​Liver​Neoadjuvant + adjuvant​MK3475-750
OTSP-HCC1 Longitudinal Immune-phenotyping of Surgically Resected HCC following Neoadjuvant and Adjuvant Treatment with MK – 3475
​Dr Toh Han ChongNCT04224480​Open
23​Liver​Adv 1st lineJS001-027-III-HCC
A prospective, randomized, placebo-controlled, double-blind, multicenter phase III registration clinical study to compare Toripalimab (JS001) combined with Lenvatinib versus placebo combined with Lenvatinib as the 1st-line therapy for advanced hepatocellular carcinoma (HCC)
​Dr Joycelyn LeeNCT04523493​Open
24​Lung​LOCALLY ADVANCED/ METASTATIC - First Line ​BO29554
A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)
​Dr Daniel Tan NCT03178552​Open
25​Lung​LOCALLY ADVANCED/ METASTATIC - First LineMK-3475-495
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)
​Dr Daniel Tan NCT03516981​Open
26​Lung​​LOCALLY ADVANCED/ METASTATIC - 2nd LineMS200095-0031
A Phase II single arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior 1st to 3rd generation EGFR-tyrosine kinase inhibitor therapy (INSIGHT2)
​Dr Daniel TanNCT03940703​Open
27​Lung​​LOCALLY ADVANCED/ METASTATIC - First LineTAK-788-3001
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
​Dr Tanujaa NCT04129502​Open
28​Lung​locally advanced or metastatic, 1st lineATORG-0003
A Single-arm, Open-label, Phase 2 Study of Dacomitinib with or without dose titration for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in subjects with an epidermal growth factor receptor (EGFR) activation mutation
​Dr Daniel TanNCT04027647​Open
29​Lung​Adjuvant stage II-III MeRmaiD-1
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC
​Dr Daniel TanNCT04385368​Open
30​Lung​Adjuvant stage II-III MERMAID-2
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy
​Dr Daniel TanNCT04642469​Open
31​​Lung​LA NSCLCCA209-73L
A Phase 3, Randomized, Open-Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)
​Dr Daniel TanNCT04026412​Open
32​Lung​Mets NSCLCLIBRETTO-431 - J2G-MC-JZJC
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing LOXO-292 to Platinum-Pemetrexed Chemotherapy Plus Investigator’s Choice of Pembrolizumab in Patients with Advanced, Treatment-Naïve RET Fusion-Positive Non-Small Cell Lung Cancer
​Dr Daniel TanNCT04194944​Open
33​Lung​​Mets NSCLCHERTHENA-Lung01
A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects with Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)
​Dr Darren LimNCT04619004​Open
​34​Lung​Mets NSCLCTROPION-LUNG01 / DS1062-A-U301
Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer without Actionable Genomic Alterations
​Dr Amit JainNCT04656652​Open
35​Nasopharyngeal​​Neoadjuvant / Stage IVA​NEO-SPACE
Neoadjuvant Pembrolizumab-Gemcitabine-Cisplatin followed by Concurrent Pembrolizumab-Chemoradiation and Maintenance Pembrolizumab for Stage IVA Nasopharyngeal Cancer
​Dr Darren LimNCT03734809​Open
36​Nasopharyngeal

Metastatic or recurrent nasopharyngeal carcinoma

No more than 1 line

​​CA209-796
A phase II trial of Ipililumab in combination with nivolumab in patients with advanced nasopharyngeal carcinoma
​Dr Darren LimNCT03097939​Open
37​Nasopharyngeal

​Metastatic or recurrent nasopharyngeal carcinoma

First line

NRG-HN007
An open-label, phase III study of platinum-gemcitabine with or without nivolumab in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma
​Dr Darren LimNCT04458909​Open
38​Prostate​MetastaticCA209-7Dx
A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (CheckMate 7DX: CHECKpoint pathway and nivoluMAB clinical Trial Evaluation 7DX)
​Dr Ng Quan SingNCT04100018​On hold
39​Prostate​MetastaticXL184-315 (CONTACT-02)
A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer
​Dr Ng Quan SingNCT04446117​Open
40​Renal​​Resectable Renal Cancer​​CA209-914
A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse
​Dr Ravindran KanesvaranNCT03138512​Open
41​​Sarcoma​relapsed/refractory​​E7080-G000-230 (OLIE)
A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma
​​Dr Mohamad FaridNCT04154189​Open


General

​No Site​ ​Stage of cancer ​Title of study ​Principal investigator ​Details of trial ​Status
​1​SOLID TUMORS ​LOCALLY ADVANCED / METASTATIC - ANY LINE CLDK378A2X01B
An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored certinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib
​Dr Daniel Tan NCT02584933​Open
​2​SOLID TUMORS ​LOCALLY ADVANCED / METASTATIC - ANY LINELOXO-TRK-15002 (NAVIGATE)
A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors
​Dr Daniel Tan NCT02576431​Open
​3​SOLID TUMORS​​LOCALLY ADVANCED/ METASTATIC – 1st and 2nd Line OnwardsAPL10101 
Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
​Dr Gillianne LaiNCT03175224​Open
4​SOLID TUMORS ​LOCALLY ADVANCED/ METASTATIC – 2nd Line OnwardsCNIR178X2201
A Phase 2, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected advanced solid tumors and non-Hodgkin lymphoma
​Dr Daniel Tan NCT03207867​Open
5​SOLID TUMORS​​LOCALLY ADVANCED/ METASTATIC – 1st and 2nd Line OnwardsTPX-0005-01
A Phase 1/2, Open-Label, Multi-Center, First-In-Human Study of the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 rearrangements (TRIDENT-1)
​Dr Darren LimNCT03093116Open
6SOLID TUMORS
(currently only HCC and gastric cohorts are opened)

Advanced curatively unresectable solid tumors failing standard therapy.

HCC: must have failed at least 1 line of standard therapy

Gastric cancer: must have failed at least 2 line of standard therapy (inclusive of adjuvant treatment)

Other solid tumours: must have failed at least 1 line of standard therapy

NCCS-2018-Phase2-PRL3
An open label Phase II study of the efficacy and tolerability of PRL3-ZUMAB and predictive biomarkers in advanced solid tumours
​Dr Matthew NgNCT04118114Open